share_log

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BriaCell展示2024年海豐國際會議上個性化現貨免疫療法管線的強大抗癌活性
GlobeNewswire ·  11/08 20:50
  • BriaCell's clinical candidates for next generation breast cancer (Bria-BRES+) and prostate cancer (Bria-PROS+) generate robust anti-cancer activity in preclinical models
  • Novel therapy activates both innate and adaptive immune systems
  • Proof of concept Phase 1/2 Study of Bria-BRES in metastatic breast cancer currently underway
  • BriaCell的臨床候選藥物Bria-BRES+和Bria-PROS+在臨床前模型中產生強大的抗癌活性
  • 新療法激活先天免疫和適應免疫系統
  • Bria-BRES轉移性乳腺癌的概念驗證1/2期研究目前正在進行中

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-BRES+ and Bria-PROS+, respectively, during a poster session at the 2024 Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX.

PHILADELPHIA和VANCOUVER,2024年11月08日(環球新聞通訊社)--BriaCell Therapeutics Corp.(納斯達克:BCTX,BCTXW)(TSX:BCT)(「BriaCell」或「公司」),一家開發新型免疫治療改變癌症護理的臨床生物技術公司,今天高興地報告其下一代個性化現成細胞基乳腺癌和前列腺癌免疫療法Bria-BRES+和Bria-PROS+的臨床前數據顯示強大的抗癌活性,在2024年11月6日至10日於得克薩斯州休斯敦舉行的第39屆Society for Immunotherapy of Cancer(SITC)年會的海報展示期間

Bria-OTS+ is an Off-The-Shelf (i.e. pre-manufactured and ready for use) cell-based personalized immunotherapy platform for cancer. First generation Bria-OTS immunotherapy is HLA matched to individual patients and expresses a variety of cancer-related antigens, including Tumor-Associated Antigens (TAAs) and Post-Translational Modifications (PTMs). Bria-OTS+ further expresses multiple immune activating cytokines and co-stimulatory molecules in addition to immune boosting granulocyte-macrophage colony-stimulating factor (GM-CSF). The Bria-OTS+ platform technology includes both Bria-BRES+ and Bria-PROS+, expansions of the Bria-OTS program.

Bria-OTS+是用於癌症的現成(即預先製造並可立即使用)基於細胞的個性化免疫療法平台。第一代Bria-OTS免疫療法與個體患者的HLA相匹配,並表達各種與癌症相關的抗原,包括腫瘤相關抗原(TAAs)和岀翻譯後修飾(PTMs)。 Bria-OTS+還表達多種免疫激活的細胞因子和共刺激分子,以及免疫增強性粒細胞-巨噬細胞集落刺激因子(Gm-CSF)。Bria-OTS+平台技術包括Bria-OTS計劃的擴展Bria-BRES+和Bria-PROS+

"Bria-OTS+ represents a significant advancement in the fight against cancer, leveraging gene-modified allogeneic tumor cells as a comprehensive immunotherapeutic platform. This innovative approach is set to address major challenges in cancer therapy, including effective antigen selection, T-cell immune escape, and manufacturing complexities. The development of Bria-OTS+ builds on the success of BriaCell's initial platform, Bria-IMT, which has shown promising clinical results in metastatic breast cancer," commented Miguel A. Lopez-Lago, PhD, BriaCell's Chief Scientific Officer.

「Bria-OTS+代表了癌症治療中的重大進步,利用基因修飾的異基因腫瘤細胞作爲全面的免疫治療平台。這種創新方法旨在解決癌症治療中的主要挑戰,包括有效的抗原選擇、細胞免疫逃逸和製造複雜性。Bria-OTS+的開發建立在BriaCell首個平台Bria-IMt的成功基礎上,後者在轉移性乳腺癌中展現了有望的臨床結果,」 Miguel A. Lopez-Lago博士,BriaCell首席科學官評論道

"We are thrilled with our pre-clinical data confirming the expected high potency and potential for long-lasting anti-tumor activity of our novel next-generation immunotherapy in multiple cancer models," commented Dr. William V. Williams, BriaCell's President and CEO. "We believe that activating both adaptive and innate immune systems is a novel and highly effective approach for cancer treatment and look forward to generating proof of concept data in our ongoing Phase 1/2 study of Bria-OTS in metastatic breast cancer, and other cancers."

我們對我們的預臨床數據感到非常激動,證實了我們新一代免疫治療藥物在多種癌症模型中預期的高效力和潛在持久的抗腫瘤活性。威廉·威廉姆斯博士,BriaCell的總裁兼首席執行官評論說:「我們相信激活適應性和先天免疫系統對癌症治療是一種新穎且高效的方法,並期待在Bria-OTS在轉移性乳腺癌及其他癌症的1/2期研究中產生概念驗證的數據。」

The poster is summarized below and linked here: .

海報內容如下,並附鏈接: .

Title: Bria-OTS+: A Cellular Cancer Vaccine Platform Targeting Innate and Adaptive Immunity
Location: Exhibit Halls A B George R. Brown Convention Center, Houston, TX
Date and Time: Friday, Nov. 8, 2024, 9:00 am -7:00 pm CST

標題:Bria-OTS+:一個針對先天免疫和適應性免疫的細胞癌症疫苗平台
地點: 德克薩斯州休斯敦喬治R. 布朗會議中心展覽廳A和B
日期和時間: 2024年11月8日,上午9:00 - 下午7:00,中部標準時間

Results:

結果:

  • Both Bria-BRES+ (clinical candidate for breast cancer) and Bria-PROS+ (clinical candidate for prostate cancer) activated key components of the innate immune system, the body's first line of defense against cancer, including Natural Killer (NK) cells and NKT cells in preclinical cancer models.
  • Activation of the innate immune system by Bria-BRES+ and Bria-PROS+ was mediated by CD86, IL-12, NKG2D and inhibited by HLA class I molecules
  • Bria-BRES+ and Bria-PROS+ both effectively activated immune cells to destroy breast cancer and prostate cancer cells in a pre-clinical cancer model
  • Both Bria-BRES+ and Bria-PROS+ activated key adaptive immune responses demonstrating immunological memory and suggesting potent and durable anti-cancer effects in cancer patients
  • Bria-BRES+(乳腺癌臨床候選藥物)和Bria-PROS+(前列腺癌臨床候選藥物)激活了先天免疫系統的關鍵元件,這是身體對抗癌症的第一道防線,包括自然殺傷細胞(NK細胞)和NKt細胞在臨床前癌症模型中。
  • Bria-BRES+和Bria-PROS+通過CD86、IL-12、NKG2D介導了先天免疫系統的激活,並受到HLA-I類分子的抑制。
  • Bria-BRES+和Bria-PROS+都有效地激活了免疫細胞,在臨床前癌症模型中摧毀了乳腺癌和前列腺癌細胞。
  • Bria-BRES+和Bria-PROS+均激活了關鍵的適應性免疫應答,展示了免疫記憶,表明對癌症患者具有強效和持久的抗癌效果。

Conclusion:
The characteristics of the next generation Bria-OTS+ immunotherapy platform include the following:

結論:
下一代Bria-OTS+免疫治療平台的特點包括以下內容:

  • Engages multiple facets of the adaptive immune response
  • Activates components of the innate immune system
  • Specifically activates Natural Killer (NK) cells to offset cancer immune escape caused by the loss of human leukocyte antigens (HLA)
  • Designed for both personalized and ready-to-use therapy with long-term stability
  • Simplified intradermal administration (injection into the skin)
  • Targeted mechanism of action expected drive high efficacy with a favorable side effect profile
  • 涉及適應性免疫反應的多個方面
  • 激活先天免疫系統的組分
  • 特異性激活自然殺傷細胞(NK細胞),以抵消由於人類白細胞抗原(HLA)丟失而導致的癌細胞免疫逃逸
  • 設計用於個性化和即用療法,具有長期穩定性
  • 簡化的皮內給藥(注射進皮膚)
  • 預期具有高效的有利副作用配置文件的靶向作用機制

"The preclinical data demonstrating targeted activation of both the innate and adaptive immune systems suggest potential efficacy and safety across multiple cancer indications," stated Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the University of Pittsburgh School of Medicine and Medical Director of the Magee-Women's Cancer Program. "Personalized off-the-shelf cancer immunotherapy is an especially exciting treatment modality that would benefit many cancer patients."

通過臨床前數據顯示,有針對性激活先天和獲得性免疫系統的潛在療效和安全性,可跨多種癌症適應症,匹茲堡大學醫學院醫學教授、梅奇-婦女癌症項目醫學主任亞當·M·布魯夫斯基博士表示。 "個性化即插即用癌症免疫療法尤其令人振奮,將使許多癌症患者受益。"

BriaCell is currently conducting its Phase 1/2 Study of Bria-OTS (first generation product), also known as Bria-BRES, in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06471673). This is a bucket trial with other cancer indications expected to be added soon. The next generation (Bria-OTS+) is expected to enter the clinic in 1H2025 starting with Bria-PROS+ for prostate cancer.

BriaCell目前正在進行Bria-OTS(第一代產品,也稱爲Bria-BRES)的1/2期研究,治療轉移性乳腺癌(在ClinicalTrials.gov上編號爲NCT06471673)。這是一個多中心臨床試驗,其他癌症適應症有望很快加入。下一代產品(Bria-OTS+)預計將於2025年上半年進入臨床,首先推出Bria-PROS+,用於治療前列腺癌。

Bria-OTS+ leverages advanced biomanufacturing techniques, ensuring scalability and cost-effectiveness, crucial for rapid global deployment. It is designed to target a range of cancer types and strong intellectual property strategy protects Bria-OTS+ innovations and strengthens BriaCell's competitive position. Bria-OTS+ is designed as an open-ended, modular platform, allowing for continuous refinement and the addition of new components. This flexibility enables BriaCell to rapidly adapt to emerging scientific insights and therapeutic needs, ensuring long-term relevance and effectiveness.

Bria-OTS+利用先進的生物製造技術,確保可擴展性和成本效益,這對快速全球部署至關重要。它旨在針對一系列癌症類型,強大的知識產權戰略保護了Bria-OTS+的創新並增強了BriaCell的競爭地位。Bria-OTS+設計爲一個開放式、模塊化平台,可持續改進並添加新元件。這種靈活性使BriaCell能夠迅速適應新興科學見解和治療需求,確保長期的相關性和有效性。

About BriaCell Therapeutics Corp.

關於BriaCell Therapeutics Corp。

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at .

BriaCell是一家臨床階段的生物技術公司,開發新穎的免疫療法,改變癌症治療。更多信息請訪問。

Safe Harbor

免責聲明

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about Bria-OTS+ addressing certain challenges in cancer therapy, such as effective antigen selection, T-cell immune escape, and manufacturing complexities; BriaCell generating proof of concept data in the ongoing Phase 1/2 study of Bria-OTS+ in various cancers, such as metastatic breast cancer; the preclinical data of Bria-OTS+ demonstrating potential efficacy and safety across multiple cancer indications; BriaCell's personalized off-the-shelf immunotherapy benefiting many cancer patients; BriaCell continuing its clinical study investigations of its novel targeted immunotherapy candidates, including the addition of new cancer indications; and BriaCell's anticipated timeline of clinical studies on Bria-OTS+ and Bria-PROS+, are based on BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

本新聞稿包含"前瞻性陳述",受到重大風險和不確定性的影響。除歷史事實陳述之外,在本新聞稿中包含的所有陳述均屬前瞻性陳述。本新聞稿中包含的前瞻性陳述可通過使用諸如"預期"、"相信"、"考慮"、"可能"、"估計"、"預期"、"打算"、"尋求"、"可能"、"或許"、"計劃"、"潛力"、"預測"、"項目"、"目標"、"瞄準"、"應該"、"將"、"將會"或這些詞的否定形式或其他類似表達方式來識別,儘管並非所有前瞻性陳述都包含這些詞。前瞻性陳述,包括有關Bria-OTS+解決癌症治療中的某些挑戰,如有效抗原選擇、萬億.細胞免疫逃逸和製造複雜性;BriaCell在正在進行的Bria-OTS+一/二期研究中產生概念驗證數據的前瞻性陳述,涉及各種癌症,如轉移性乳腺癌;Bria-OTS+的臨床前數據顯示了在多個癌症適應症中的潛在療效和安全性;BriaCell的個性化現成免疫療法造福於許多癌症患者;BriaCell繼續對其新型靶向免疫療法候選藥物進行臨床研究調查,包括增加新的癌症適應症;及BriaCell對Bria-OTS+和Bria-PROS+臨床研究時間表的預期,均基於BriaCell目前的預期,並受難以預測的固有不確定性、風險和假設的影響。此外,某些前瞻性陳述,如那些基於未來事件的假設的陳述,可能未能證明準確。這些和其他風險和不確定性在公司最新的管理層討論與分析報告的「風險與不確定性」部分下更詳細地描述,在公司最新的年度信息表的「風險因素」部分下,在公司對加拿大證券監管機構和美國證券交易委員會的其他文件中的「風險與不確定性」部分中均有描述,這些文件均可在SEDAR+上查看,網址爲,以及在EDGAR上的www.sec.gov。本公告中包含的前瞻性陳述截至本日期,並且BriaCell Therapeutics Corp.除依法規定外無義務更新此類信息。

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所及其監管服務提供商(該術語的定義在多倫多證券交易所政策中)對本發佈的充分性或準確性不承擔責任。

Contact Information

聯繫信息

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com

公司聯繫人:
William V. Williams,MD
總裁兼首席執行官
1-888-485-6340
info@briacell.com

Media Relations:
Jules Abraham
CORE IR
julesa@coreir.com

媒體關係:
Jules Abraham
CORE IR
julesa@coreir.com

Investor Relations Contact:
CORE IR
investors@briacell.com

投資者關係聯繫人:
CORE IR
investors@briacell.com


譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論